Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

HIV-Related Lymphoma Differs in Those With Early vs Advanced HIV Infection

April 1, 2002
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 4
Volume 11
Issue 4

HOUSTON-Physicians at Ben Taub General Hospital, Houston, noticed that an unusual number of patients were presenting with lymphoma as their first AIDS-defining event. This observation prompted a retrospective study of all HIV-positive patients with non-Hodgkin’s lymphoma presenting between 1989 and 2000.

HOUSTON—Physicians at Ben Taub General Hospital, Houston, noticed that an unusual number of patients were presenting with lymphoma as their first AIDS-defining event. This observation prompted a retrospective study of all HIV-positive patients with non-Hodgkin’s lymphoma presenting between 1989 and 2000.

Indeed, the analysis showed that 33 (35%) of the 88 patients identified in the study were newly diagnosed with HIV, whereas 55 were known to be HIV positive when their lymphoma was diagnosed, Suleiman Alfred Massarweh, MD, told ONI in an interview. In other cohorts of patients with HIV-related lymphoma, he noted, only 3% to 5% typically present with lymphoma as their first AIDS-defining illness.

This discrepancy may be explained, in part, by Ben Taub’s status as a community hospital. The hospital serves as the first destination for these patients at presentation, thus eliminating potential referral bias. "Most patients in the large cohorts already have their HIV diagnosis when they go to these referral centers," Dr. Massarweh said at the 43rd Annual Meeting of the American Society of Hematology (abstract 1434). He is a clinical fellow at Baylor College of Medicine.

The substantial number of newly diagnosed HIV patients with lymphoma in the Ben Taub database gave the Houston researchers a unique opportunity to compare these patients with lymphoma patients with known HIV infection.

Of the 55 known-HIV patients presenting with lymphoma in the study, 10 had no history of an AIDS-defining illness and were being followed by primary care physicians in the HIV clinic. The rest had a previous AIDS-defining event before their lymphoma presentation.

Burkitt’s Lymhoma

Dr. Massarweh noted that the new-HIV lymphoma patients tended to be a few years older than the known-HIV patients: an average of 41 vs 38 years.

A more important finding was that the new-HIV patients were significantly more likely to have Burkitt’s or Burkitt’s-like lymphoma. Conversely, the known-HIV patients, who typically were more immunocompromised, were more likely to have diffuse large B cell immunoblastic lymphoma.

In addition, gastrointestinal involvement was rare in the new-HIV patients, but was very strongly associated with known HIV. "Out of the 33 new-HIV patients, only one had GI involvement at diagnosis. The other 14 cases of GI involvement were in the known-HIV group," Dr. Massarweh said.

He noted that in most previous studies involving large cohorts, the investigators did not distinguish among different lymphoma types when determining trends in the incidence and outcome of AIDS-related lymphoma. "They put everything together," he said. "Central nervous system lymphoma should be out of the equation; it should be looked at separately because we know it occurs in very advanced patients with very low CD4 counts."

The Ben Taub cohort, he said, suggests that not all systemic lymphomas are the same either. "There is a variety that can develop in patients who do not have advanced immunosuppression, and this category may be amenable to treatments to reconstitute the immune system," he said. "These patients may be more likely to respond to their lymphoma therapy and have a chance of long survival."

The fact that patients with early HIV infection still develop lymphoma suggests, Dr. Massarweh said, that some pathogenetic pathway other than prolonged low CD4 counts may be responsible. "It might be due to other factors such as an endogenous cytokine imbalance," he said.

Articles in this issue

Infection Rate Low With Peripheral and Nontunneled CVCs Nontunneled Catheters
Virtual Shared Specimen Resource ‘Essential’
DHA Conjugate Increases Paclitaxel Uptake by Tumor Cells
Letrozole Superior to Tamoxifen in Metastatic Breast Cancer
S-8184 Paclitaxel Emulsion Promising in Phase I Study
HIV+ Veterans Have Higher Rates of Unusual Cancers
A Clinician’s Perspective on ASCO 2001: Going After the Epidermal Growth Factor Receptor
Online Breast Cancer Support Groups Beneficial
Survival Benefit With Capecitabine/Docetaxel
FDA Approves Zometa for Cancer-Related Bone Complications
New Blood Test for Early Ovarian Cancer in Clinical Trials
Race Per Se Does Not Predict Extracapsular Prostate Cancer
HIV-Related Lymphoma Differs in Those With Early vs Advanced HIV Infection
Equal Access Erases Racial Disparity in Prostate Cancer Stage
FDA Approves Zevalin for Use With Rituxan in Refractory NHL Patients
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Related Content
Advertisement

Serplulimab plus chemotherapy also achieved a threefold higher pathological complete response rate and a significant reduction in the risk of recurrence compared with the control arm.

Serplulimab Plus Chemo Meets EFS End Point in Early-Stage Gastric Cancer

Tim Cortese
October 10th 2025
Article

An independent data monitoring committee suggested the submission of an early NDA for serplulimab plus chemotherapy in early-stage gastric cancer.


A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP
October 6th 2025
Podcast

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.


A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor-positive GEP-NETs.

212Pb-Dotamtate Prolongs Responses in Advanced GEP-NETs

Roman Fabbricatore
October 10th 2025
Article

A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor–positive GEP-NETs.


Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.


Adding a focal boost to EBRT reduced the number of biochemical failures by more than 50%.

EBRT Plus Focal Boost Sustains Biochemical DFS Benefit in Prostate Cancer

Tim Cortese
October 9th 2025
Article

The 10-year biochemical DFS rate was 86% with EBRT plus focal boost vs 71% with standard EBRT in those with intermediate- and high-risk prostate cancer.


The primary end points of the trial included the incidence of dose-limiting toxicities with monotherapy and combination therapy and the incidence of treatment-emergent adverse events.

FDA Grants FTD to WTX-124 in Advanced Pretreated Cutaneous Melanoma

Tim Cortese
October 9th 2025
Article

Data from a phase 1/1b trial showed that WTX-124 achieved clinically meaningful activity in those with advanced melanoma following SOC immunotherapy.

Related Content
Advertisement

Serplulimab plus chemotherapy also achieved a threefold higher pathological complete response rate and a significant reduction in the risk of recurrence compared with the control arm.

Serplulimab Plus Chemo Meets EFS End Point in Early-Stage Gastric Cancer

Tim Cortese
October 10th 2025
Article

An independent data monitoring committee suggested the submission of an early NDA for serplulimab plus chemotherapy in early-stage gastric cancer.


A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP
October 6th 2025
Podcast

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.


A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor-positive GEP-NETs.

212Pb-Dotamtate Prolongs Responses in Advanced GEP-NETs

Roman Fabbricatore
October 10th 2025
Article

A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor–positive GEP-NETs.


Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.


Adding a focal boost to EBRT reduced the number of biochemical failures by more than 50%.

EBRT Plus Focal Boost Sustains Biochemical DFS Benefit in Prostate Cancer

Tim Cortese
October 9th 2025
Article

The 10-year biochemical DFS rate was 86% with EBRT plus focal boost vs 71% with standard EBRT in those with intermediate- and high-risk prostate cancer.


The primary end points of the trial included the incidence of dose-limiting toxicities with monotherapy and combination therapy and the incidence of treatment-emergent adverse events.

FDA Grants FTD to WTX-124 in Advanced Pretreated Cutaneous Melanoma

Tim Cortese
October 9th 2025
Article

Data from a phase 1/1b trial showed that WTX-124 achieved clinically meaningful activity in those with advanced melanoma following SOC immunotherapy.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.